Moventig - supply shortage
Ongoing
Shortage
Human
Shortage information
There is a shortage of Moventig in some EU/EEA (European Economic Area) countries.
Moventig is a medicine used in adults to treat constipation caused by pain relief medicines called opioids. It is used in patients in whom treatment with laxatives has failed.
For further information on the use of the medicine please refer to the medicine’s overview page.
Supply constraints and unexpected demand surges in some EU/EEA countries have led to a temporary shortage of both dosages of Moventig tablets. The shortage is not related to a quality defect or a safety issue with Moventig itself.
The shortage is expected to last until the end of November 2025, but precise timing will vary across Member States.
The shortage affects some of the countries where the product is marketed:Austria, Denmark, Finland, France, Germany, Ireland, Sweden and Norway.
This information may change. For up-to-date information about the status of a medicine shortage in a particular EU/EEA country, consult the national shortage register or contact the national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- A shortage of both dosages of Moventig tablets is ongoing in some EU/EEA countries. The shortage is expected to resolve by the end of November 2025.
- While Moventig is unavailable, healthcare professionals should consider alternative treatment options for their patients. The following therapeutic alternatives (with different active substance) may be available in some EU/EEA countries:
- Relistor (methylnaltrexone) is indicated for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older;
- Rizmoic (naldemedine) is indicated for the treatment of opioid-induced constipation in adult patients who have previously been treated with a laxative.
- For additional information consult your country’s shortage register or contact your national competent authority.
- A shortage of Moventig 12.5 mg and 25 mg tablets is ongoing in some EU/EEA countries. The shortage is expected to resolve by the end of November 2025.
- Contact your pharmacy or doctor well before your current supply runs out so that they can prescribe an alternative medicine for you.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Key facts
- Medicines affected
- Moventig
- Supply shortage status
- Ongoing
- Strengths affected
- 12.5 mg
- 25 mg
- Availability of alternatives
- Yes
Key dates
- Expected resolution
- 31 November 2025
- First published